Keep reading:
Why Endonovo Therapeutics Holds Plenty Of Upside Potential For Investors
Jun. 5.15 | About: Endonovo Therapeutics, (ENDV)
Jason Ihaji
Jason Ihaji
Long/short equity, portfolio strategy, tech, oil & gas
(20 followers)
Summary
About 25 million Americans live with some kind of rare disease creating an extremely lucrative market for firms developing rare disease treatments.
The market for these drugs is expected to grow to $176 billion by 2020 according to EvaluatePharma's Orphan Drug Report 2014.
Currently, Endonovo Therapeutics presents an attractive entry point into this market based on a number of factors highlighted in the article.
Background
While a number of you may not have heard of Endonovo Therapeutics (OTCQB:ENDV) before, here is what you need to know. According to its website, "Endonovo means to renew from within. Our mission is to extend and enhance the human life by regenerating tissues and organs without the use of stem cell transplants."
As of the time of this article, the firm's stock price is $1 with a total market capitalization of about $97 million. Currently, the firm generates no revenue from its operations which leads to the question: where is the potential? I had an exclusive interview with Endonovo CEO, Alan Collier, who shed more light on why investors need to seriously examine the firm's potential and why he believes that a bright future lies ahead.
Apart from being arguably one of the most competitive sectors, biotech stocks have also been on a roll if the chart below is anything to go by. This confirms that biotechs currently present a lucrative opportunity for investors. As the growth of these stocks is dependent on meeting milestones from clinical trials to FDA approval and finally commercialization, I believe that Endonovo possesses the capability to revolutionize how some of the rarest and some of the most common diseases that you have never heard of are treated.
https://seekingalpha.com/symbol/ENDV/latest
Why Endonovo Therapeutics Holds Plenty Of Upside Potential For Investors
Jun. 5.15 | About: Endonovo Therapeutics, (ENDV)
Jason Ihaji
Jason Ihaji
Long/short equity, portfolio strategy, tech, oil & gas
(20 followers)
Summary
About 25 million Americans live with some kind of rare disease creating an extremely lucrative market for firms developing rare disease treatments.
The market for these drugs is expected to grow to $176 billion by 2020 according to EvaluatePharma's Orphan Drug Report 2014.
Currently, Endonovo Therapeutics presents an attractive entry point into this market based on a number of factors highlighted in the article.
Background
While a number of you may not have heard of Endonovo Therapeutics (OTCQB:ENDV) before, here is what you need to know. According to its website, "Endonovo means to renew from within. Our mission is to extend and enhance the human life by regenerating tissues and organs without the use of stem cell transplants."
As of the time of this article, the firm's stock price is $1 with a total market capitalization of about $97 million. Currently, the firm generates no revenue from its operations which leads to the question: where is the potential? I had an exclusive interview with Endonovo CEO, Alan Collier, who shed more light on why investors need to seriously examine the firm's potential and why he believes that a bright future lies ahead.
Apart from being arguably one of the most competitive sectors, biotech stocks have also been on a roll if the chart below is anything to go by. This confirms that biotechs currently present a lucrative opportunity for investors. As the growth of these stocks is dependent on meeting milestones from clinical trials to FDA approval and finally commercialization, I believe that Endonovo possesses the capability to revolutionize how some of the rarest and some of the most common diseases that you have never heard of are treated.
https://seekingalpha.com/symbol/ENDV/latest
